Why the study?
To improve treatment for CHD and type 2 diabetes, clarification of pathogenetic mechanisms such as endothelial dysfunction is needed.
Endothelial dysfunction markers such as E-selectin, endothelin-1, and von Willebrand factor play a key role in the pathogenesis of CHD and type 2 diabetes.
Endothelial markers merit prospective validation in CHD with diabetes; leaves open their utility for risk stratification or therapy guidance.
The prevalence of coronary heart disease (CHD) and type 2 diabetes mellitus (type 2 diabetes) in Russia and in the world continues to increase. Despite the prevention and optimization of therapy, CHD retains its leadership among all causes of death, and the mortality rate from type 2 diabetes and its complications gradually increases too. To improve the treatment of the above mentioned diseases, it is necessary to clarify the pathogenetic mechanisms of their development. The formation of endothelial dysfunction, characterized by an increase in the level of cell adhesion molecules and vasoconstriction, is a common link characteristic for the course and progression of CHD and type 2 diabetes. This article presents an analysis of preand clinical studies on the role of endothelial dysfunction markers: cell adhesion molecules (E-selectin), vasoconstriction (endothelin-1) and von Willebrand factor in patients with CHD, including those with type 2 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Zhito et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: